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Introduction: Thymic malignancies are rare intrathoracic tumors
that may be aggressive and difficult to treat in advanced stage. Over
the past years, significant efforts have been conducted to dissect the
molecular pathways involved in the carcinogenesis of these tumors.
Insights have been made following anecdotal clinical responses to
targeted therapies, and large-scale genomic analyses have been
conducted.
Methods: Review of the literature, 1990–2010.
Results: The Epidermal Growth Factor Receptor (EGFR) is fre-
quently overexpressed in thymomas and thymic carcinomas, but
EGFR mutations are exceptional, and this does not support the use
of EGFR tyrosine kinase inhibitors. On the contrary, single obser-
vations of responses create a basis for further evaluation of cetux-
imab in thymomas. KIT-mutant thymic carcinomas represent a small
molecular subset of thymic tumors. The clinical relevance of KIT
mutations is more limited in thymic carcinoma than in GIST as KIT
mutations are far less frequent (7% of thymic carcinomas) and are
not correlated with KIT expression; furthermore, KIT mutants are
not uniformly sensitive to imatinib. Beyond EGFR and KIT signal-
ing pathways, other molecular alterations with potential prognostic
or predictive relevance are emerging in thymic malignancies.
Conclusions: Given the rarity of these tumors, translation of pre-
clinical findings to the clinic may be quick and represents one of the
most promising therapeutic approaches for advanced-stage thymic
malignancies.
Key Words: Thymoma, Thymic carcinoma, Epidermal growth
factor receptor, Biology, KIT, Chemotherapy.
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Thymic malignancies are rare intrathoracic tumors thatmay be aggressive and difficult to treat in advanced
stage.1 The current histopathologic classification distin-
guishes thymomas (types A, AB, B1, B2, B3) and thymic
carcinoma2 based on the morphology of epithelial cells (with
an increasing degree of atypia from type A to thymic carci-
noma), the relative proportion of the nontumoral lymphocytic
component (decreasing from types B1 to B3), and resem-
blance to normal thymic architecture.2 After surgery, thymo-
mas have a tendency toward local and regional progression,
whereas thymic carcinomas are highly aggressive tumors
with frequent systemic involvement at time of diagnosis and
poor prognosis despite multimodal treatment including sur-
gery, radiotherapy, and chemotherapy.3,4 Beyond histology,
tumor invasiveness as evaluated by the Masaoka et al.3
staging system is a major prognostic indicator. However, the
most significant prognostic factor in thymic tumors is
whether the tumor may undergo complete resection or not.4
Cancers results from the accumulation of multiple mo-
lecular alterations including oncogene activation and tumor
suppressor gene inactivation.5 Large-scale genomic analyses
suggest that, beyond stage or histology, cancers may be
subdivided in molecular subsets, based on expression,
genomic, mutational, and proteomic profiling data. Among
these multiple molecular alterations, only a few are consid-
ered to be “driver” of the oncogenesis process, i.e., necessary
and sufficient for cancer development and maintenance, a
concept also called “oncogene addiction.”6 These driver mu-
tations are as “Achille heels” that can predict response to
specific targeted agents. Beyond a predictive value, molecular
alterations may have a prognostic significance on time-to-
progression and overall survival.
Over the past years, significant efforts have been con-
ducted to dissect the molecular pathways involved in the
carcinogenesis of thymic malignancies.7 Research is ham-
pered by the rarity of the tumor, evolution of histopathologic
concepts, and a lack of established cell lines and animal
models. Insights in the biology of thymic tumors have also
been made following anecdotal clinical responses to targeted
therapies.8–12 Here, we review current knowledge about the
molecular biology of thymic malignancies that define molec-
ular subsets with potential clinical and therapeutic relevance.
EPIDERMAL GROWTH FACTOR PATHWAY
The epidermal growth factor receptor (EGFR) is one of
the most studied biomarkers in epithelial cancers.13 An extensive
review of the EGFR signaling pathway is out of the scope of this
article, and readers may refer to previously published reviews.13
Overall, EGFR mutations in lung adenocarcinoma are the best
illustration of the therapeutic relevance of identifying molecular
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clusters of cancer based on driver genetic alterations. The pres-
ence of EGFR activating mutations in lung tumor cells is a
strong predictor of efficacy of specific inhibitors, gefitinib
(Iressa, AstraZeneca, Macclefields, UK) and erlotinib (Tarceva,
Roche, Basel, Switzerland), with response rates and progres-
sion-free survival significantly higher than after standard
platinum-based doublet chemotherapy (70 versus 30%, and
9.5 versus 6.3 months, respectively).14 Beyond these muta-
tions, EGFR amplification has also been identified as a
predictor of response to these agents, as well as to cetuximab,
a humanized monoclonal antibody targeting EGFR (Erbitux,
Merk, Darmstadt, Germany).
Downstream EGFR, KRAS is a GTPase transducing
signal from the membrane to cytoplasmic proteins.13 In lung
cancer, KRAS may present with activating mutations that are
mutually exclusive with EGFR mutations.6,13 KRAS-mutant
tumors then represent a specific molecular subset of cancers
for which EGFR inhibitors are not effective.
EGFR Signaling Pathway Biomarkers in Thymic
Tumors
Several studies investigated EGFR expression levels in
thymic tumors using immunohistochemistry (Table 1).7,15–21
EGFR was overexpressed in 70% of thymomas and 53% of
thymic carcinomas. Collectively, there was no strong corre-
lation between EGFR staining and thymic tumor type (p 
0.23, 2 test) (Table 1). Higher EGFR staining was signifi-
cantly associated with stage III to IV tumors (p  0.023, 2
test) in two studies.7,18
EGFR copy number status was measured in one study
including 32 patients with thymomas or thymic carcinomas.22
In this study, EGFR was significantly amplified in type B3
thymomas. The degree of EGFR amplification as measured
by fluorescence in situ hybridization poorly correlated with
EGFR overexpression but was higher in stage II to IV versus
stage I tumors (p  0.005).
EGFR mutations are rare in thymic malignan-
cies.7,11,18–20,23,24 Thus far, only three EGFR mutations have
been found out of a total of 158 tumors collectively analyzed.
The mutations were L858R in two cases and G863D in one
case,20,24 which are both associated with response to EGFR
inhibitors in lung cancer. There was no correlation between
EGFR expression and EGFR mutational status.
Regarding EGFR downstream proteins, no mutation
has been identified in the following genes: PIK3CA, AKT1,
ERBB2, MEK1, and PTEN.8 RAS mutations were observed in
3 (7%) out of 45 thymic epithelial tumors from Memorial
Sloan-Kettering Cancer Center series.8 One mutation was a
G12A KRAS mutation, one was a G12V KRAS mutation, and
one was an HRAS G13V mutation.8 Of the 17 thymic tumors
assessed elsewhere for KRAS status,11,23,25 no mutation had
been identified.
Clinical Significance
Together with the presence of RAS mutations, the low
frequency of EGFR activating mutations in thymic tumors
may explain why responses to EGFR inhibitors have been
rarely observed.23,26 One phase II trial with gefitinib was
conducted in patients with chemorefractory thymic tumors.
Among 19 thymomas and 7 thymic carcinomas, partial re-
sponse and stable disease were observed in 1 and 14 patients,
respectively.23 Several observations of heavily pretreated
recurrent thymoma exhibiting partial response to cetuximab
have been reported.12,27 All tumors harbored strong EGFR
expression by immunohistochemistry. A phase II trial is
ongoing that evaluates the feasibility of delivering cetux-
imab in combination with the standard cyclophosphamide,
adriamycin, and platin regimen in unresectable thymomas
(clinicaltrails.gov ID: NCT01025089).
KIT SIGNALING PATHWAY
KIT is a transmembrane growth factor with tyrosine
kinase activity whose ligand is the scatter cell factor. KIT
plays a major role in the development and maintenance of
gastrointestinal stromal tumors (GISTs), which overexpress
KIT in 95% of cases.28 KIT expression has been associated
with activating mutations occurring in exons 9 (extracellular
domain), 11 (juxta-membrane domain), 13 (first kinase do-
main), and 17 (activation loop) of the KIT gene.28 These
mutations lead to constitutive activation of the KIT kinase.
The discovery of KIT mutations revolutionized the treatment
of GISTs, which is associated with poor outcome when
treated with chemotherapy. On the contrary, the use of
Imatinib mesylate (Gleevec, Novartis, Basel), an oral KIT
inhibitor leads to rapid, substantial, and durable tumor re-
sponses.29 Interestingly, not all KIT mutations are associated
with equal sensitivity to imatinib,30 and second-generation
KIT inhibitors have been developed.
KIT Biomarkers in Thymic Tumors
The pooled analysis of data reported in the literature
indicates that collectively, KIT is overexpressed in 2% of
thymomas and 79% of thymic carcinomas (p  0.001; 2
test) (Table 2).31–34 All immunohistochemistry studies used
the same anti-KIT rabbit polyclonal antibody from Dako
(Carpinteria, CA). Given the significantly highest frequency
of KIT expression in thymic carcinoma, some authors pro-
posed KIT as a diagnostic marker of thymic carcinoma versus
thymoma in the setting of a mediastinal tumor.32
TABLE 1. Studies Reporting EGFR Expression by
Immunohistochemistry in Thymic Malignancies
References
Thymoma Thymic Carcinoma
n
EGFR
Overexpression,
n (%) n
EGFR
Overexpression,
n (%)
Pescarmona et al.15 15 15 (100%) NA NA
Gilhus et al.16 24 24 (100%) NA NA
Henley et al.17 31 26 (84%) 6 2 (33%)
Suzuki et al.18 52 22 (42%) 4 4 (100%)
Meister et al.19 17 16 (94%) 3 1 (33%)
Yoh et al.20 21 15 (71%) 17 9 (53%)
Girard et al.7 33 18 (33%) 6 5 (83%)
Aisner et al.21 34 24 (69%) 5 1 (20%)
EGFR, epidermal growth factor receptor; NA, not applicable.
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Despite the frequent expression of KIT, KIT mutations
are found only in 7% of thymic carcinomas (5/70 collectively
analyzed) (Table 3).7–9,20,34–36 The mutation was in two
cases a V560 deletion, that was previously observed in
imatinib-responsive GISTs.7,8 Another KIT mutation was
an L576P substitution,20 which had been identified in GIST
and melanoma as an imatinib- and sunitinib-sensitive mu-
tation.30 The third mutation was a D820E mutation, that
was found in a patient with thymic carcinoma responding
to sorafenib tosylate (BAY43-9006; Nexavar; Bayer, West
Haven, CT).35 This residue is known to frequently harbor
imatinib-resistant mutations.30 The fourth KIT mutation was
an H697Y mutation in exon 14, which was characterized in
vitro to be associated with higher sensitivity to sunitinib than
to imatinib.7
Clinical Significance
KIT-mutant thymic carcinomas represent a small mo-
lecular subset of thymic tumors. The clinical relevance of KIT
mutations is more limited in thymic carcinoma than in GIST,
because (1) KIT mutations are far less frequent; (2) KIT
expression does not correlate with the presence of KIT mu-
tation; and (3) nonpretreated KIT mutants are not uniformly
sensitive to imatinib (Table 3). These findings may explain
why 2 phase II trials with imatinib, where patients were
selected based on histologic type (B3 thymomas and thymic
carcinomas)36 or KIT staining by immunohistochemistry37
and not on KIT genotyping, were negative.
Given the existence of molecular platforms that rou-
tinely genotype KIT in GIST, one option would be to sys-
tematically sequence KIT in thymic carcinoma tumors. Ulti-
mately, the use of imatinib should not be recommended in
mutant cases, given the higher efficacy of second-generation
inhibitors and the results of available clinical trials.38
IGF-1R PATHWAY
Insuilin-like growth factor-1 receptor (IGF-1R) is a
transmembrane receptor that was previously reported to be
frequently overexpressed in squamous cell carcinomas.39,40
Although not identified so far as a driver molecular alteration,
IGF-1R activation participates in multiple processes involved
in oncogenesis. IGF-1R activation has also been linked to
resistance to EGFR inhibitors through formation of EGFR/
IGF-1R heterodimers, continued activation of the PI3K-AKT
pathway and inhibition of the pro-apoptotic protein sur-
vivin.39 Interestingly, the growth of cell lines harboring high
IGF-1R expression levels was more readily inhibited after
exposure to R1507, a monoclonal antibody against IGF-1R.40
IGF-1R Expression in Thymic Tumors
IGF-1R expression was studied by immunohistochem-
istry in a cohort of 63 thymic tumors.41 Moderate to high
IGF-1R expression was more frequent in thymic carcinomas
than in thymomas (86 versus 43% respectively, p  0.039),
and was associated with higher EGFR staining (p  0.015 in
the whole cohort; p  0.034 in thymomas). IGF-1R expres-
sion level was not a significant prognostic variable on time-
to-progression at multivariate analysis (OR  3.07; 95%
CI  0.38–24.59; p  0.291).
Clinical Significance
Figitumumab (CP751,871; Pfizer), an anti-IGF1-R an-
tibody,42 recently showed clinical activity in a patient with
refractory thymoma.43 A phase II trial is ongoing evaluating
IMC-A12 (ImClone Systems Incorporated, Branchburg, NJ),
another anti-IGF-1R antibody, in advanced and refractory
thymomas and thymic carcinomas (clinicaltrials.gov ID:
NCT00965250).
ANGIOGENESIS INHIBITION
Neovascularization is a crucial process in the develop-
ment and progression of cancer that is mandatory when
tumors grow beyond 1 cm3 in volume.44 Numerous proan-
giogenesis factors regulating the proliferation of endothelial
cells have been identified, which stimulate vasculature forma-
tion, growth of the primary tumor, and migration of tumor cells
to the systemic circulation. The most potent proangiogenic
molecules are those of the vascular endothelial growth factor
(VEGF) receptor (VEGFR) signaling pathway. VEGFRs are
found on the surface of endothelial cells and vascular peri-
cytes, promote angiogenesis, and stimulate cell migration,
proliferation, and survival.
In 2003, VEGF was validated as a clinically relevant
target in renal cell carcinoma in a landmark randomized
phase II trial comparing the effect of placebo with the
anti-VEGF antibody bevacizumab (rhuMAb-VEGF, Avastin,
Genentech, San Francisco, CA).45 Bevacizumab significantly
prolonged time-to-progression of patients.45 In lung cancer,
the addition of bevacizumab to chemotherapy confers a
TABLE 3. Growth-Inhibitory Drug Effects in Cell Lines
Containing KIT-Mutations Identified in Thymic Carcinomas
Mutation Exon Imatinib Sunitinib Dasatinib Nilotinib
V560del 11    
L576P 11    
D820E 17 0 0  
H697Y 14   NE NE
0, half maximal inhibitory concentration (IC50) 1000 nM, resistance; , IC50
between 500 and 1000 nM, low sensitivity; , IC50 between 100 and 500 nM,
mid-sensitivity; , IC50  100 nM, high-sensitivity; NE, not evaluated.
Data compiled from Ref. 7.
TABLE 2. Studies Reporting KIT Expression in Thymic
Tumors
References
Thymoma Thymic Carcinoma
n
KIT
Overexpression,
n (%) N
KIT
Overexpression,
n (%)
Pan et al.31 110 0 (0%) 22 19 (86%)
Henley et al.32 20 1 (5%) 15 12 (80%)
Nakagawa et al.33 50 2 (1%) 20 16 (80%)
Yoh et al.20 24 0 (0%) 17 15 (88%)
Tsuchida et al.34 20 0 (0%) 12 11 (92%)
Girard et al.7 33 0 (0%) 6 3 (50%)
Aisner et al.21 34 2 (6%) 5 1 (20%)
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2-month survival benefit to patients with nonsquamous tu-
mors over those receiving chemotherapy alone.46 VEGF or
VEGFR expression levels do not appear to be consistent
predictive markers of response to bevacizumab.
VEGFR Expression in Thymic Tumors
VEGF-A and VEGFR-1 and -2 are overexpressed in
thymomas and thymic carcinomas.47 Microvessel density and
VEGF expression levels have been shown to correlate with
tumor invasion and clinical stage.48 Patients with thymic
carcinoma have increased levels of VEGF in the serum, what
is not observed in patients with thymoma.49
Clinical Significance
Only sparse data is available regarding the use of
angiogenesis inhibitors in thymic malignancies. In a phase II
trial, bevacizumab was tested in combination with erlotinib in
11 thymomas and 7 thymic carcinomas.26 No tumor response
was observed. In a phase I study combining docetaxel with
aflibercept, a soluble receptor that binds VEGF-A (also called
VEGF trap), one patient with thymoma experienced partial
response.50 Interestingly, despite the large tumor burden of
thymic tumors and the frequent abutment to mediastinal
vascular structures, no hemorrhagic side-effect has been re-
ported with the use of these drugs in these studies.
Multikinase inhibitors may also be of interest to target
angiogenesis. Beyond the inhibition of KIT, sunitinib and
sorafenib also inhibit VEGFR-1, VEGFR-2, VEGFR-3 at the
nanomolar range. The effect of these drugs in thymic carci-
noma tumors may then be partially related to an antiangio-
genic effect.9,10,35 As sunitinib and sorafenib, motesanib
diphosphonate (AMG-706; Amgen, Thousand Oaks, CA) is a
specific inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, which
was reported to control the growth of a thymic carcinoma
tumor refractory to chemotherapy for 12 months.51
OTHER GENETIC ALTERATIONS
The increasing access of clinicians to molecular
profiling platforms for cancer research leads to the rapid
identification of additional genetic alterations that may be
predictive or prognostic in thymic malignancies. Transla-
tion to the clinic may be easier with the concurrent devel-
opment of specific targeted agents. In this setting, several
investigators recently showed that cyclin-dependent kinase
(CDK) proteins that control the cell cycle G1-S phases
transition, may be altered through p16INK4 loss in thymo-
mas.52 A phase II trial with a CDK inhibitor, PHA-848125AC
has been launched in advanced thymic tumors (clinicaltrials.
gov ID: NCT01011439).
Another avenue of interest is the identification of prog-
nostic markers that may help to select patients with thymic
malignancies for aggressive treatment, including postopera-
tive radiotherapy and chemotherapy.2 However, the favorable
outcome of thymic tumors after surgery and the highly
significant value of R0 resection make the identification of
such prognostic factors challenging. A recent report identified
high EGFR and low KIT expression as being associated with
longer time-to-progression after treatment with octreotide.21
Another study suggested that high P53 with low P21and P27
expression levels might predict overall survival of patients
(hazard ratio  11.6; 95% CI  1.49–102.63; p  0.02).53
These findings are preliminary data that need to be validated
independently in further studies.
To conclude, the concept of personalized molecular
medicine, which consists of selecting patients for available
targeted therapies based on predictive biomarkers, is ap-
plicable to rare tumors such as thymomas and thymic
carcinomas. Research efforts are currently being con-
ducted to dissect the molecular biology of thymic malig-
nancies. Given the rarity of the tumor, translation of preclin-
ical findings to the clinic may be quick and represents one of
the most promising therapeutic approaches for advanced-
stage thymic malignancies.
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